| DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo KJ Thompson, E Khajehali, SJ Bradley, JS Navarrete, XP Huang, ... ACS Pharmacology & Translational Science 1 (1), 61-72, 2018 | 163 | 2018 |
| G protein-coupled receptor signalling in astrocytes in health and disease: a focus on metabotropic glutamate receptors SJ Bradley, RAJ Challiss Biochemical pharmacology 84 (3), 249-259, 2012 | 81 | 2012 |
| M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss SJ Bradley, JM Bourgognon, HE Sanger, N Verity, AJ Mogg, DJ White, ... The Journal of clinical investigation 127 (2), 487-499, 2017 | 70 | 2017 |
| Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder RAW Frank, AF McRae, AJ Pocklington, LN van de Lagemaat, P Navarro, ... PLoS One 6 (4), e19011, 2011 | 63 | 2011 |
| Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent “compound 2” at the GLP-1 receptor K Coopman, Y Huang, N Johnston, SJ Bradley, GF Wilkinson, GB Willars Journal of Pharmacology and Experimental Therapeutics 334 (3), 795-808, 2010 | 57 | 2010 |
| Mapping physiological G protein-coupled receptor signaling pathways reveals a role for receptor phosphorylation in airway contraction SJ Bradley, CH Wiegman, MM Iglesias, KC Kong, AJ Butcher, B Plouffe, ... Proceedings of the National Academy of Sciences 113 (16), 4524-4529, 2016 | 54 | 2016 |
| Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia SJ Bradley, CJ Langmead, JM Watson, RAJ Challiss Molecular pharmacology 79 (5), 874-885, 2011 | 53 | 2011 |
| Chemogenetics defines receptor-mediated functions of short chain free fatty acids D Bolognini, N Barki, AJ Butcher, BD Hudson, E Sergeev, C Molloy, ... Nature Chemical Biology 15 (5), 489-498, 2019 | 50 | 2019 |
| Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats TM Visarius, H Bähler, A Küpfer, T Cerny, BH Lauterburg Drug Metabolism and Disposition 26 (3), 193-196, 1998 | 48 | 1998 |
| From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease AJH Brown, SJ Bradley, FH Marshall, GA Brown, KA Bennett, J Brown, ... Cell 184 (24), 5886-5901. e22, 2021 | 47 | 2021 |
| Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs SJ Bradley, C Molloy, P Valuskova, L Dwomoh, M Scarpa, M Rossi, ... Nature chemical biology 16 (3), 240-249, 2020 | 43 | 2020 |
| Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias ET Van der Westhuizen, KHC Choy, C Valant, S McKenzie-Nickson, ... Frontiers in pharmacology 11, 606656, 2021 | 40 | 2021 |
| M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease? M Scarpa, S Hesse, SJ Bradley Advances in pharmacology 88, 277-310, 2020 | 40 | 2020 |
| An Antibody Biosensor Establishes the Activation of the M1 Muscarinic Acetylcholine Receptor during Learning and Memory*♦ AJ Butcher, SJ Bradley, R Prihandoko, SM Brooke, A Mogg, ... Journal of Biological Chemistry 291 (17), 8862-8875, 2016 | 37 | 2016 |
| Design of next-generation G protein–coupled receptor drugs: linking novel pharmacology and in vivo animal models SJ Bradley, AB Tobin Annual review of pharmacology and toxicology 56, 535-559, 2016 | 32 | 2016 |
| Inhibition of neuroinflammatory nitric oxide signaling suppresses glycation and prevents neuronal dysfunction in mouse prion disease JM Bourgognon, JG Spiers, SW Robinson, H Scheiblich, P Glynn, C Ortori, ... Proceedings of the National Academy of Sciences 118 (10), e2009579118, 2021 | 31 | 2021 |
| Determination of GPCR phosphorylation status: establishing a phosphorylation barcode R Prihandoko, SJ Bradley, AB Tobin, AJ Butcher Current Protocols in Pharmacology 69 (1), 2.13. 1-2.13. 26, 2015 | 30 | 2015 |
| Effects of positive allosteric modulators on single-cell oscillatory Ca2+ signaling initiated by the type 5 metabotropic glutamate receptor SJ Bradley, JM Watson, RAJ Challiss Molecular Pharmacology 76 (6), 1302-1313, 2009 | 29 | 2009 |
| Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes SJ Bradley, C Molloy, C Bundgaard, AJ Mogg, KJ Thompson, L Dwomoh, ... Molecular pharmacology 93 (6), 645-656, 2018 | 28 | 2018 |
| Alterations in neuronal metabolism contribute to the pathogenesis of prion disease JM Bourgognon, JG Spiers, H Scheiblich, A Antonov, SJ Bradley, ... Cell Death & Differentiation 25 (8), 1408-1425, 2018 | 27 | 2018 |
